Innovent Bio's NSCLC Drug Gets China Approval

MT Newswires Live

Jan 03, 2025

Innovent Biologics (HKG:1801) said China's National Medical Products Administration approved the second new drug application of Dovbleron to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

The other approved indication is for patients with locally advanced or metastatic ROS1-positive NSCLC previously treated with ROS1 TKI, according to a Friday filing with the Hong Kong bourse.

Dovbleron, or taletrectinib adipate capsule, is a next-generation ROS proto-oncogene 1 (ROS1) tyrosine kinase inhibitor. The Food and Drug Administration granted it Orphan Drug Designation for several NSCLC indications, the filing stated.

Price (HKD): $36.25, Change: $+0.75, Percent Change: +2.11%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2500366761"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2500366761\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2500366761?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-03 10:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500366761","market":"hk","top_or_hot":-1,"title":"Innovent Bio's NSCLC Drug Gets China Approval","media":"MT Newswires Live","content":"<html><body><p> Innovent Biologics (HKG:1801) said China's National Medical Products Administration approved the second new drug application of Dovbleron to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).</p><p>The other approved indication is for patients with locally advanced or metastatic ROS1-positive NSCLC previously treated with ROS1 TKI, according to a Friday filing with the Hong Kong bourse.</p><p>Dovbleron, or taletrectinib adipate capsule, is a next-generation ROS proto-oncogene 1 (ROS1) tyrosine kinase inhibitor. The Food and Drug Administration granted it Orphan Drug Designation for several NSCLC indications, the filing stated.</p><p>Price (HKD): $36.25, Change: $+0.75, Percent Change: +2.11%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Bio's NSCLC Drug Gets China Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Bio's NSCLC Drug Gets China Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-03 10:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Innovent Biologics (HKG:1801) said China's National Medical Products Administration approved the second new drug application of Dovbleron to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).</p><p>The other approved indication is for patients with locally advanced or metastatic ROS1-positive NSCLC previously treated with ROS1 TKI, according to a Friday filing with the Hong Kong bourse.</p><p>Dovbleron, or taletrectinib adipate capsule, is a next-generation ROS proto-oncogene 1 (ROS1) tyrosine kinase inhibitor. The Food and Drug Administration granted it Orphan Drug Designation for several NSCLC indications, the filing stated.</p><p>Price (HKD): $36.25, Change: $+0.75, Percent Change: +2.11%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1969619763.USD","symbol_name":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2500366761","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500366761","pubTimestamp":1735870641,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Innovent Biologics  said China's National Medical Products Administration approved the second new drug application of Dovbleron to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer .The other approved indication is for patients with locally advanced or metastatic ROS1-positive NSCLC previously treated with ROS1 TKI, according to a Friday filing with the Hong Kong bourse.Dovbleron, or taletrectinib adipate capsule, is a next-generation ROS proto-oncogene 1  tyrosine kinase inhibitor. The Food and Drug Administration granted it Orphan Drug Designation for several NSCLC indications, the filing stated.Price : $36.25, Change: $+0.75, Percent Change: +2.11%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1583":"高瓴概念","BK1589":"北水核心资产","HKD":"尚乘数科","BK4526":"热门中概股","01801":"信达生物","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","BK4023":"应用软件","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"信达生物非小细胞肺癌药物获中国批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"01801":0.9},"content_text":"Innovent Biologics (HKG:1801) said China's National Medical Products Administration approved the second new drug application of Dovbleron to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).The other approved indication is for patients with locally advanced or metastatic ROS1-positive NSCLC previously treated with ROS1 TKI, according to a Friday filing with the Hong Kong bourse.Dovbleron, or taletrectinib adipate capsule, is a next-generation ROS proto-oncogene 1 (ROS1) tyrosine kinase inhibitor. The Food and Drug Administration granted it Orphan Drug Designation for several NSCLC indications, the filing stated.Price (HKD): $36.25, Change: $+0.75, Percent Change: +2.11%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}